Lancet Diabetes Endocrinol. 2017;5(4):251–60. 6. Ahre´n B, Masmiquel L, Kumar H, et al. Efﬁcacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add- on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–54. 7. Aroda VR, Bain SC, Cariou B, et al. Efﬁcacy and safety of once- weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open- label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–66. 8. Ahmann AJ, Capehorn M, Charpentier G, et al. Efﬁcacy and safety of once-weekly semaglutide versus exenatide ER in sub- jects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial.